Repeat Ivermectin Mass Drug Administrations for MALaria Control II (RIMDAMAL II): a double-blind, cluster-randomized control trial for integrated control of malaria.

Colorado State University0 个研究点目标入组 4,700 人开始时间: 2019年6月29日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Residence in selected study village
•Able to understand the information and willing to give consent or assent (age 12-18) and parent/guardian consent if study participant age is < 18 years of age.

•Residence outside of the study village
•Height < 90 cm (*note: if subject becomes =90cm over course the trial, this exclusion criteria will no longer be valid in subsequent MDA)
•Current treatment with SP+AQ as part of SMC (restricted to children 3-48 months old) (*note: if subject discontinuous SP+AQ treatment because they become older than 48 months over course the trial, this exclusion criteria will no longer be valid in subsequent MDA)
•Permanent disability or serious medical illness that prevents or impedes study participation and/or comprehension
•Pregnancy (screened for in women of child-bearing age [ages 15-45] using a pregnancy urine rapid test [e.g. SD Bioline hCG] the week prior to each MDA)
•Breast feeding if infant is within 1 week of birth Known allergy to ivermectin
•Possibility of Loa loa infection as assessed by travel history to Angola, Cameroon, Chad, Central African Republic, Congo, Democratic Republic of Congo, Equatorial Guinea, Ethiopia, Gabon, Nigeria, and Sudan.
•Enrolled in any other active clinical trials

发起方